Mostrar el registro sencillo del ítem

Artículo

dc.creatorRodríguez Gil, Alfonsoes
dc.creatorEscamilla Gómez, Virginiaes
dc.creatorNufer, Melaniees
dc.creatorAndújar Sánchez, Félixes
dc.creatorLopes Ramos, Teresaes
dc.creatorBejarano García, José Antonioes
dc.creatorCaballero Velázquez, Teresaes
dc.creatorVilladiego Luque, Francisco Javieres
dc.creatorPérez Simón, José Antonioes
dc.date.accessioned2022-11-28T14:30:20Z
dc.date.available2022-11-28T14:30:20Z
dc.date.issued2022
dc.identifier.citationRodríguez Gil, A., Escamilla Gómez, V., Nufer, M., Andújar Sánchez, F., Lopes Ramos, T., Bejarano García, J.A.,...,Pérez Simón, J.A. (2022). Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib. Scientific Reports, 12 (1), 8348. https://doi.org/10.1038/s41598-022-12407-x.
dc.identifier.issn2045-2322es
dc.identifier.urihttps://hdl.handle.net/11441/139859
dc.description.abstractDonor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic efect in the treatment of GvHD. For this purpose, we studied the efect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without afecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efcacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia efect. This benefcial efect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.es
dc.formatapplication/pdfes
dc.format.extent13 p.es
dc.language.isoenges
dc.publisherNature Publishing Groupes
dc.relation.ispartofScientific Reports, 12 (1), 8348.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectGraft versus host diseasees
dc.subjectRegulatory T cellses
dc.subjectRuxolitinibes
dc.titleCombined treatment of graft versus host disease using donor regulatory T cells and ruxolitinibes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Fisiología Médica y Biofísicaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-022-12407-xes
dc.identifier.doi10.1038/s41598-022-12407-xes
dc.journaltitleScientific Reportses
dc.publication.volumen12es
dc.publication.issue1es
dc.publication.initialPage8348es

FicherosTamañoFormatoVerDescripción
Combined treatment.pdf6.085MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional